Goldman Sachs analyst Paul Choi downgraded Edgewise Therapeutics (EWTX) to Neutral from Buy with a $20 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- JPMorgan cuts Edgewise target, remains from Analyst Focus List
- Edgewise Therapeutics Advances in Muscular Dystrophy Trials
- Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls